[144] Idexx Laboratories Inc SEC Filing
Form 144 notice for IDEXX Laboratories (IDXX) reports a proposed sale of 407 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $264,533.53. The filing lists the company's outstanding shares as 80,004,694, so the proposed sale represents approximately 0.00051% of outstanding stock. The acquisition history provided shows the shares originated from multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, with acquisition dates ranging from 06/30/2021 through 03/29/2024. The filer certifies they are not aware of undisclosed material adverse information and uses Morgan Stanley as the executing broker. The proposed approximate sale date is 08/12/2025.
Avviso Form 144 relativo a IDEXX Laboratories (IDXX) segnala una proposta di vendita di 407 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $264,533.53. Il deposito indica che le azioni in circolazione sono 80,004,694, quindi la vendita proposta rappresenta circa 0.00051% del capitale sociale. La cronologia delle acquisizioni mostra che le azioni derivano da pi霉 acquisti nell'ambito dell'Employee Stock Purchase Plan e da una concessione di Restricted Stock, con date di acquisizione dal 06/30/2021 al 03/29/2024. Il dichiarante certifica di non essere a conoscenza di informazioni riservate sfavorevoli non divulgate e indica Morgan Stanley come broker esecutore. La data approssimativa proposta per la vendita 猫 il 08/12/2025.
Aviso Form 144 para IDEXX Laboratories (IDXX) informa una propuesta de venta de 407 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ, con un valor de mercado agregado de $264,533.53. La presentaci贸n indica que las acciones en circulaci贸n son 80,004,694, por lo que la venta propuesta representa aproximadamente el 0.00051% del capital social. El historial de adquisici贸n muestra que las acciones provienen de varias compras del Employee Stock Purchase Plan y de una concesi贸n de Restricted Stock, con fechas de adquisici贸n desde el 06/30/2021 hasta el 03/29/2024. El declarante certifica que no tiene conocimiento de informaci贸n adversa material no divulgada y utiliza a Morgan Stanley como corredor ejecutor. La fecha aproximada propuesta para la venta es el 08/12/2025.
IDEXX Laboratories (IDXX)鞐� 雽�頃� Form 144 韱奠电� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 407欤检潣 氤错喌欤� 毵り皝鞚� 鞝滌晥頄堨溂氅�, 齑� 鞁滉皜齑濎暋鞚� $264,533.53霛缄碃 氤搓碃頃╇媹雼�. 鞁犼碃靹滌棎电� 氚滍枆欤检嫕靾橁皜 80,004,694搿� 旮办灛霅橃柎 鞛堨柎 鞝滌晥霅� 毵り皝鞚� 氚滍枆欤检嫕鞚� 鞎� 0.00051%鞐� 頃措嫻頃潉 雮橅儉雰呺媹雼�. 旆摑 鞚措牓鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 鞐煬 彀鞚� Employee Stock Purchase Plan 甑Г鞕赌 Restricted Stock 攵�鞐棎靹� 氚滌儩頄堨溂氅�, 旆摑鞚检潃 06/30/2021攵赌韯� 03/29/2024旯岇鞛呺媹雼�. 鞝滌稖鞛惖鐢 瓿奠嫓霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歃濍獏頃橁碃 鞛堨溂氅�, 鞁ろ枆 欷戧皽鞚胳溂搿� Morgan Stanley毳� 歆�鞝曧枅鞀惦媹雼�. 鞝滌晥霅� 雽�霝奠爜鞚� 毵り皝鞚检潃 08/12/2025鞛呺媹雼�.
Avis Form 144 pour IDEXX Laboratories (IDXX) signale une proposition de vente de 407 actions ordinaires par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande globale de $264,533.53. Le d茅p么t indique que le nombre d'actions en circulation est de 80,004,694, de sorte que la vente propos茅e repr茅sente environ 0.00051% du capital social. L'historique des acquisitions montre que les actions proviennent de plusieurs achats dans le cadre du Employee Stock Purchase Plan et d'une attribution de Restricted Stock, avec des dates d'acquisition allant du 06/30/2021 au 03/29/2024. Le d茅clarant certifie ne pas avoir connaissance d'informations d茅favorables mat茅rielles non divulgu茅es et utilise Morgan Stanley comme courtier ex茅cutant. La date approximative propos茅e pour la vente est le 08/12/2025.
Form 144-Mitteilung f眉r IDEXX Laboratories (IDXX) meldet einen vorgeschlagenen Verkauf von 407 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $264,533.53. Die Einreichung nennt die ausstehenden Aktien mit 80,004,694, sodass der vorgeschlagene Verkauf etwa 0.00051% des ausstehenden Kapitals ausmacht. Die Erwerbshistorie zeigt, dass die Aktien aus mehreren K盲ufen im Rahmen des Employee Stock Purchase Plan und einer Zuteilung von Restricted Stock stammen, mit Erwerbsdaten vom 06/30/2021 bis zum 03/29/2024. Der Einreichende best盲tigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind, und benennt Morgan Stanley als ausf眉hrenden Broker. Das voraussichtliche ungef盲hre Verkaufsdatum ist der 08/12/2025.
- Complete disclosure of broker, exchange, proposed sale date, and aggregate market value
- Acquisition history provided showing Employee Stock Purchase Plan and Restricted Stock origins
- Filer certification that no undisclosed material adverse information is known
- None.
Insights
TL;DR: Small insider sale notice: 407 shares valued at $264,533.53鈥攏egligible versus 80,004,694 outstanding shares.
The Form 144 documents a planned sale under Rule 144 for 407 common shares using Morgan Stanley as broker with an aggregate value of $264,533.53. Given the stated 80,004,694 shares outstanding, the sale equals roughly 0.00051% of the float, indicating the transaction is immaterial to company capital structure. The filing includes a clear acquisition record showing multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, and the filer affirms no undisclosed material adverse information. From a market-impact perspective, the notice signals compliance rather than a material shift in ownership.
TL;DR: Compliance-focused filing: disclosure of provenance and broker details; sale size is trivial relative to outstanding shares.
The Form 144 provides the necessary disclosure elements: broker name (Morgan Stanley Smith Barney LLC), exchange (NASDAQ), proposed sale date (08/12/2025), and a detailed acquisition history (ESPP and Restricted Stock entries). The filer also makes the standard certification regarding material non-public information. These items demonstrate adherence to disclosure rules for an insider sale; nothing in the filing raises governance or compliance concerns based on the information presented.
Avviso Form 144 relativo a IDEXX Laboratories (IDXX) segnala una proposta di vendita di 407 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $264,533.53. Il deposito indica che le azioni in circolazione sono 80,004,694, quindi la vendita proposta rappresenta circa 0.00051% del capitale sociale. La cronologia delle acquisizioni mostra che le azioni derivano da pi霉 acquisti nell'ambito dell'Employee Stock Purchase Plan e da una concessione di Restricted Stock, con date di acquisizione dal 06/30/2021 al 03/29/2024. Il dichiarante certifica di non essere a conoscenza di informazioni riservate sfavorevoli non divulgate e indica Morgan Stanley come broker esecutore. La data approssimativa proposta per la vendita 猫 il 08/12/2025.
Aviso Form 144 para IDEXX Laboratories (IDXX) informa una propuesta de venta de 407 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ, con un valor de mercado agregado de $264,533.53. La presentaci贸n indica que las acciones en circulaci贸n son 80,004,694, por lo que la venta propuesta representa aproximadamente el 0.00051% del capital social. El historial de adquisici贸n muestra que las acciones provienen de varias compras del Employee Stock Purchase Plan y de una concesi贸n de Restricted Stock, con fechas de adquisici贸n desde el 06/30/2021 hasta el 03/29/2024. El declarante certifica que no tiene conocimiento de informaci贸n adversa material no divulgada y utiliza a Morgan Stanley como corredor ejecutor. La fecha aproximada propuesta para la venta es el 08/12/2025.
IDEXX Laboratories (IDXX)鞐� 雽�頃� Form 144 韱奠电� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 407欤检潣 氤错喌欤� 毵り皝鞚� 鞝滌晥頄堨溂氅�, 齑� 鞁滉皜齑濎暋鞚� $264,533.53霛缄碃 氤搓碃頃╇媹雼�. 鞁犼碃靹滌棎电� 氚滍枆欤检嫕靾橁皜 80,004,694搿� 旮办灛霅橃柎 鞛堨柎 鞝滌晥霅� 毵り皝鞚� 氚滍枆欤检嫕鞚� 鞎� 0.00051%鞐� 頃措嫻頃潉 雮橅儉雰呺媹雼�. 旆摑 鞚措牓鞐� 霐半ゴ氅� 頃措嫻 欤检嫕鞚� 鞐煬 彀鞚� Employee Stock Purchase Plan 甑Г鞕赌 Restricted Stock 攵�鞐棎靹� 氚滌儩頄堨溂氅�, 旆摑鞚检潃 06/30/2021攵赌韯� 03/29/2024旯岇鞛呺媹雼�. 鞝滌稖鞛惖鐢 瓿奠嫓霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歃濍獏頃橁碃 鞛堨溂氅�, 鞁ろ枆 欷戧皽鞚胳溂搿� Morgan Stanley毳� 歆�鞝曧枅鞀惦媹雼�. 鞝滌晥霅� 雽�霝奠爜鞚� 毵り皝鞚检潃 08/12/2025鞛呺媹雼�.
Avis Form 144 pour IDEXX Laboratories (IDXX) signale une proposition de vente de 407 actions ordinaires par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande globale de $264,533.53. Le d茅p么t indique que le nombre d'actions en circulation est de 80,004,694, de sorte que la vente propos茅e repr茅sente environ 0.00051% du capital social. L'historique des acquisitions montre que les actions proviennent de plusieurs achats dans le cadre du Employee Stock Purchase Plan et d'une attribution de Restricted Stock, avec des dates d'acquisition allant du 06/30/2021 au 03/29/2024. Le d茅clarant certifie ne pas avoir connaissance d'informations d茅favorables mat茅rielles non divulgu茅es et utilise Morgan Stanley comme courtier ex茅cutant. La date approximative propos茅e pour la vente est le 08/12/2025.
Form 144-Mitteilung f眉r IDEXX Laboratories (IDXX) meldet einen vorgeschlagenen Verkauf von 407 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $264,533.53. Die Einreichung nennt die ausstehenden Aktien mit 80,004,694, sodass der vorgeschlagene Verkauf etwa 0.00051% des ausstehenden Kapitals ausmacht. Die Erwerbshistorie zeigt, dass die Aktien aus mehreren K盲ufen im Rahmen des Employee Stock Purchase Plan und einer Zuteilung von Restricted Stock stammen, mit Erwerbsdaten vom 06/30/2021 bis zum 03/29/2024. Der Einreichende best盲tigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind, und benennt Morgan Stanley als ausf眉hrenden Broker. Das voraussichtliche ungef盲hre Verkaufsdatum ist der 08/12/2025.
FAQ
What does the IDEXX (IDXX) Form 144 report?
When is the proposed sale date on the IDXX Form 144?
How significant is the proposed sale relative to IDEXX's outstanding shares?
What is the origin of the shares being sold in the IDXX Form 144?
Who is the executing broker named in the Form 144 for IDXX?
